Login to Your Account

Exelixis Getting $195M Up Front in BMS Cancer Collaboration

By Catherine Hollingsworth

Monday, December 15, 2008
Exelixis signed a major deal with Bristol-Myers Squibb Co., in which the drugmaker would pay a hefty $195 million up front for rights to cancer programs developed by Exelixis. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription